A Retrospective Study to Determine the Impact of Psychedelic Therapy for Dimensional Measures of Wellness: A Quantitative Analysis

This pre-print of an observational study (n=65) examines the impact of psychedelic medicines on wellness among civilian or military veterans who self-identified as using these substances for non-recreational purposes in the past three years. Participants reported improvements in all domains (pain, mental health, function, and overall quality of life), with the highest perceived improvement in mental health and overall quality of life, and lowest in pain. The results suggest a significant association between the perceived changes in all domains, regardless of the specific psychedelic substance used.

Abstact of A Retrospective Study to Determine the Impact of Psychedelic Therapy for Dimensional Measures of Wellness

Background: The World Health Organization (WHO) defines wellness as the optimal state of health of individuals and groups. No study to date has identified the impact of psychedelic medicines on optimizing wellness using a dimensional approach. Using this approach, treatment effects can be measured more broadly using a composite score of participants global perceptions of change for pain, function, and mood scores. Given the precedence in previous work for retrospective studies of participants self-medicating with these substances, the nature of this study design allows for a safe way to develop further evidence in this area of care, with wellness as the broad indication.

Methods: 65 civilian or military veterans above the age of 18, self-identifying as having used psychedelic medicines for non-recreational purposes in the last 3 years were recruited. Participants completed the following standardized questionnaires: Patient Global Impression of Change (PGIC) scale, Pain, Enjoyment of Life and General Activity (PEG) scale, Anxiety and Depression scale (ADS), and Disability Index (DI) scale. The analysis focused on reported PGIC outcomes and correlations between subscales. Given the nature of the study, a comparison to the baseline could not be made.

Results: On average, participants reported improvement in all domains (pain, mental health, function, and overall quality of life), regardless of the medicine. Perceived improvement was highest in mental health and overall quality of life, and lowest in pain. Kendall correlation showed a highly significant association between the perceived changes in all domains. Correlation coefficients were highest between the perceived change in function, quality of life, and mental health. Discussion: The use of various psychedelic medicines may be associated with a broad range of changes that could help clarify the mechanism of how they impact wellness in the future. Pain, mental health, function, and overall quality of life accordingly improved after the use of these medicines. Minor differences between the drugs were not found as significant, indicating that the perceived benefits seemed to be specific to the psychedelic class. Numerous limitations exist to this type of study which was relatively small in size, retrospective and anonymous in nature.

Conclusion: The wellness of individuals or groups is not simply an absence of disease, symptoms, or impairments. Instead, it is an outcome that is shaped by a myriad of personal characteristics, psychophysiology, and choices, expressed throughout ones lifespan, unfolding in dynamic interaction with a complicated sociocultural and physical environment.

Authors: Victoria Di Virgilio, Amir Minerbi, Jagpaul K. Deol, Salena Aggerwal, Toufik Safi & Gaurav Gupta

Summary of A Retrospective Study to Determine the Impact of Psychedelic Therapy for Dimensional Measures of Wellness

The World Health Organization (WHO) defines health as the complete physical, mental, and social well-being of an individual, which includes the ability to handle everyday challenges, function effectively, and give back to the community.

Research shows that the Diagnostic and Statistical Manuals (DSM) guidelines are not extremely specific, inter-rater reliability is low, and treatment outcomes are not always correlated with clinical indicators. Therefore, many authors advocate for a dimensional approach to mental health treatment.

To access this content, you must purchase one of the following memberships: Pro Membership, Pro Membership Unlimited, Business Membership or Business Membership Unlimited. The membership will give you access to exclusive data, including summaries of psychedelic research papers, extended company info, and our member-only visualisations. Save yourself multiple hours each week by accessing Blossom’s resource library.

Find this paper

A Retrospective Study to Determine the Impact of Psychedelic Therapy for Dimensional Measures of Wellness: A Quantitative Analysis

https://doi.org/10.1101/2023.05.10.23289787

Open Access | Google Scholar | Backup | 🕊

Cite this paper (APA)

Di Virgilio, V., Minerbi, A., Deol, J. K., Aggerwal, S., Safi, T. & Gupta, G. (2023). A Retrospective Study to Determine the Impact of Psychedelic Therapy for Dimensional Measures of Wellness: A Quantitative Analysis of Response Data. medRxiv, 2023-05.

Study details

Participants
65 Humans

Linked Research Papers

Notable research papers that build on or are influenced by this paper

A Retrospective Study to Determine the Impact of Psychedelic Therapy for Dimensional Measures of Wellness: A Qualitative Analysis of Response Data
This preprint qualitative analysis (n=65) of civilians and veterans finds improvements in wellness (a term used by the WHO), which includes improvements in medical and mental health conditions, social interactions, spirituality, and overall function.

PDF of A Retrospective Study to Determine the Impact of Psychedelic Therapy for Dimensional Measures of Wellness: A Quantitative Analysis